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Abstract:  The  development  of  amyloid-containing  neuritic  plaques  is  an  invariable 
characteristic  of Alzheimer’s  diseases  (AD). The  conversion  from  monomeric  amyloid  β 
protein (Aβ) to oligomeric Aβ and finally neuritic plaques is highly dynamic. The specific 
Aβ species that is correlated with disease severity remains to be discovered. Oligomeric Aβ 
has been detected in cultured cells, rodent and human brains, as well as human cerebrospinal 
fluid. Synthetic, cell, and brain derived Aβ oligomers have been found to inhibit hippocampal 
long-term potentiation (LTP) and this effect can be suppressed by the blockage of Aβ oligomer 
formation. A large body of evidence suggests that Aβ oligomers inhibit N-methyl-D-aspartate 
receptor  dependent  LTP;  additional  receptors  have  also  been  found  to  elicit  downstream 
pathways upon binding to Aβ oligomers. Amyloid antibodies and small molecular compounds 
that reduce brain Aβ levels and block Aβ oligomer formation are capable of reversing synaptic 
dysfunction and these approaches hold a promising therapeutic potential to rescue memory 
disruption.
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Alzheimer’s disease (AD) is pathologically characterized by the presence of intracellular 
neurofibrillary tangles and extracellular neuritic plaques.1 Neurofibrillary tangles are 
mainly composed of hyperphosphorylated tau protein while neuritic plaques are formed 
by a gradual accumulation of amyloid β protein (Aβ). Aβ is produced by the sequential 
cleavage of amyloid precursor protein (APP) by β-secretase and γ-secretase.1–3 The APP 
gene encodes three different splicing isoforms, APP770, APP751 and APP695. The 
ectodomain of APP contains Kunitz protease inhibitor region (KPI) that accounts for 
the major difference in precursor sizes. Earlier studies have shown that KPI containing 
APP are present in dystrophic neuritis and may be associated with Aβ production and 
senile plaque formation.4 The final cleavage by the γ-secretase determines the length of 
Aβ peptides. Among various Aβ isoforms, the most common ones are 40-residue Aβ 
(Aβ40) and 42-residue Aβ (Aβ42). The γ-secretase complex contains four components, 
presenilin 1 (PS1), nicastrin, anterior pharynx defective-1 (APH-1) and presenilin 
enhancer-2 (PEN-2).5 Two aspartate residues located at the transmembrane domain 6 
and 7 of PS1 constitute the active site of the γ-secretase.6 Nicastrin was found to 
associate with the C-terminal fragments of APP and required for γ-secretase activity.7,8 
Genetic screens in Caenorhabditis elegans revealed two additional components of the 





The temporal sequence of deposition for different 
Aβ species is critical for understanding the pathogenesis of 
neuritic plaques in brains.11 While the number of neuritic 
plaques may not be correlated to the severity of dementia 
in a linear fashion, the levels of Aβ42 are closely associated 
with the disease.12 Among a subset of nondemented subjects 
who carry classic AD pathology, as determined by Aβ immu-
noreactive plaques and thioflavin histofluorescent plaques, 
the concentration of insoluble Aβ is similar to those from 
AD patients. The soluble pool of Aβ, which could be both 
extracellular and intracellular, differentiates AD from non-
demented subjects and shows a strong inverse corelationship 
with synapse loss.13 Measuring the soluble and insoluble 
Aβ pools from another subset of AD and control subjects 
indicated that levels of total and insoluble Aβ differentiate 
AD from control subjects although not the disease severity. 
Likewise, the soluble pool of Aβ is increased threefold in 
AD subjects and correlates with disease severity.14 Patho-
logical comparison of nondemented subjects, or those at 
the very early stage of dementia, with demented subjects 
suggests that an increase in Aβ40 and Aβ42 correlates 
with the progression of dementia and precedes apparent tau 
pathology in the frontal cortex of the brain.15 Plasma Aβ42 
is also elevated in patients carrying familial Alzheimer 
disease-linked mutations in PS1, PS2 and APP genes.16 All 
autosomal dominant mutations have been found in PS and 
APP genes, and missense mutations in PS and APP genes 
account for the majority of early onset familial AD cases. 
Most of these familial AD (FAD) patients have a very early 
onset of disease, reflecting an increase of both peripheral 
and cerebral deposition of Aβ42. Among most AD patients, 
evidence suggests that a small pool of soluble Aβ may contain 
the toxic form of Aβ that causes neurodegeneration. This pool 
of Aβ may contribute to the large static pool of insoluble 
Aβ and form neuritic plaques over time.
Oligomeric Aβ and Aβ42
Biochemical analysis of the soluble pool of Aβ has revealed 
a fraction of Aβ specimens to migrate as 6–8 kDa on 
electrophoresis gel. Extracted from aged human cortical 
samples, these sodium dodecyl sulfate (SDS)-stable Aβ 
species corresponding to the size of dimers are detected by 
Western blot analysis using antibodies against Aβ. Similar 
SDS-stable Aβ dimers are also detected in brain lysates from 
PDGF-driven hAPP PDAPP transgenic mice that over express 
human APP gene.17
The Aβ dimer and higher molecular weight Aβ trimer 
have been similarly discovered in the media of Chinese 
hamster ovary (CHO) cells expressing human APP.18 These 
oligomeric Aβ have been immunoprecipitated with a number 
of Aβ antibodies, and the authenticity of Aβ peptide forming 
the dimer and trimer has been confirmed by amino acid 
sequencing.18 When CHO cells coexpress APP and a FAD-
linked mutant PS1 or PS2 gene, oligomeric Aβ has been 
detected in the culture media that contains high levels of 
Aβ42 monomers. These results clearly indicate that increase 
in Aβ42 monomers facilitate the aggregation and formation 
of Aβ oligomers.12,19
The significance of Aβ42 has been elucidated in an earlier 
report on the biochemical and pathological comparison of 
AD brains.20 A third of brains with no congophilic angiopathy 
have been found to be carrying a majority of Aβ species 
ending at residue 42.20 The same amount of Aβ42 has also 
been found in brains with substantial congophilic angiopathy, 
although these brains contain far more Aβ40. Immunohis-
tochemical staining has revealed that Aβ42 is primarily 
located in the senile plaques, while Aβ40 is mainly in blood 
vessel walls.20 The association of Aβ42 in neuritic plaques 
and disease onset appears to be the outcome of oligomer 
formation at the early stages. Biophysical analysis of syn-
thetic Aβ peptides ending at 40 and 42 pinpoints the critical 
amino acids at residue 41 and 42, isoleucine-41 (Ile-42) and 
alanine-42 (Ala-42). Aβ40 monomers and oligomers can 
quickly reach equilibrium; however, Aβ42 preferentially 
forms pentamer/hexamer followed by subsequent conversion 
to early protofibrils. The addition of residue Ile-41 to Aβ40 
facilitates the formation of pentamer/hexamer and the residue 
Ala-42 is needed for further formation of protofibrils.21 The 
major subcellular compartment that contains dimeric Aβ is 
the lipid raft, which carries a quarter of the brain’s Aβ40 and 
Aβ42. Dimeric Aβ is detected in lipid rafts from transgenic 
(Tg) Tg2576 mouse brains at 6 months when no amyloid 
plaque are present although memory impairment starts to 
emerge. The levels of dimeric Aβ continue to increase, and 
then apolipoprotein E (ApoE) and phosphorylated tau start 
to accumulate in the lipid rafts. When animals are two years 
or older, a 500 fold increase of dimeric Aβ has been found 
in the lipid rafts. Importantly, similar increases of dimeric 
Aβ, ApoE and phosphorylated tau are also found in brains 
of AD patients.22
Aβ oligomers and memory 
impairment
A disconnection of memory impairment and plaque formation 
has been explored in transgenic mice overexpressing wild type 




Aβ oligomers inhibit LTP
(SYN-IR) presynaptic terminals in specific brain regions has 
been correlated to cognitive decline in AD and used as an 
index for comparing wt and mutant APP transgenic mice. 
In transgenic mice expressing high levels of wt APP, there 
is no plaque formation even when large amounts of Aβ42 
peptides are generated. This causes a significant decrease of 
SYN-IR presynaptic terminals, which is inversely correlated 
to Aβ42 levels.23 In transgenic mice overexpressing FAD 
linked (APP V717F) mutant APP, SYN-IR presynaptic 
terminals decrease before the appearance of amyloid 
plaques.24 Significant deficits in synaptic transmission have 
been detected by electrophysiological recordings from the 
hippocampus of these mutant transgenic mice in the absence 
of plaques. When the Swedish mutation is introduced to 
APP, those transgenic mice generate more Aβ peptide with 
relatively lower expression levels of Swedish mutant APP. 
The young transgenic mice do not develop plaques although 
they do show increased synaptic transmission deficits.24 
Apparently, Aβ peptides exhibit neurotoxicity independent 
of plaque formation.
Although the neurotoxic effect of Aβ42 is observed in 
very young mice, there is a significant delay in any behavioral 
effect upon injection of aggregated Aβ42 into the hippocampi 
of rats. After rats were trained in two-lever operant chambers 
under an alternating lever cyclic-ratio schedule, aggregated 
Aβ42 was injected into the CA3 area of the hippocampus. 
Severe deficits were shown in behavioral tests at 30 days 
post injection, with much greater symptoms at 50 days post 
injection.25 Upon intracerebroventricular injection of Aβ42 
into rat brains, low-frequency stimulation induces long-term 
depression (LTD), while the low-frequency stimulation alone 
is not sufficient. Therefore, Aβ42 promotes a long-lasting 
reduction in synaptic strength and causes disruption of the 
processing that relies on hippocampal synaptic plasticity.26
The synthetic Aβ peptides have been used to generate 
low molecular weight oligomers like Aβ-derived diffusible 
ligands (ADDLs). At nanomolar concentrations, ADDLs are 
neurotoxic in vitro. ADDLs are found to inhibit hippocampal 
long-term potentiation (LTP) and affect neural signal trans-
duction.27 Synthetic ADDLs have been correlated to synapse 
loss and memory failure and their properties are highly simi-
lar to those Aβ oligomers detected in brains using antibodies 
raised against synthetic Aβ oligomers. When compared to 
control brains, more than a 70 fold increase of oligomer 
Aβ has been found in the frontal cortex of AD patients. 
Both synthetic ADDLs and brain derived oligomeric Aβ 
are found attached to cultured hippocampal neurons and 
bound to dendrite surfaces.28 When rat hippocampal slices 
were preincubated with ADDLs, Tetanus-induced LTP and 
reversal of LTD were strongly inhibited, while LTD was 
not affected.29
Aβ oligomers are formed inside cells and subsequently 
secreted into the media. Microinjection of Aβ oligomer-
containing cell media clearly inhibits hippocampal LTP in 
rats. The inhibitory effect could be blocked by removing all 
Aβs with Aβ antibodies. However, inhibition could not be 
blocked in media pretreated with insulin-degrading enzyme 
that specifically targets Aβ monomers, though not oligomers. 
On the other hand, γ-secretase inhibitors used to treat cells 
at dosages which slightly reduce Aβ monomer production 
lead to a reduction in oligomeric Aβ formation. Media from 
γ-secretase inhibitor-treated cells contain Aβ monomers, 
although not oligomers, and fail to disrupt LTP.30 The low 
number of oligomers, including the dimmers, trimers or 
tetramers, but not monomers, are found to: block the hip-
pocampal LTP; do not affect presynaptic vesicle release; 
and fail to affect LTP in juvenile mice and brain-derived 
neurotrophic-factor-induced LTP in the adult hippocampus.31 
Importantly, Aβ dimers isolated from brains of AD subjects 
have shown the same effect.32
In APP transgenic mice Tg2576, little or no neuronal cell 
loss appears concurrently with the accumulation of Aβ and 
memory impairment. Tg2576 mice younger than 6 months 
old have normal memory, middle-aged mice (6–14 months 
old) show memory deficits in the absence of neuronal loss and 
striking neuropathology, and mice at 14 months old develop 
abundant neuritic plaques. While small Aβ dimers and trimers 
derived from cultured cells are known to specifically disrupt 
cognitive function,33 a unique form of Aβ oligomer, termed 
Aβ*56, has been purified from the brains of middle-aged 
(6–14 month old) Tg2576 mice that impairs memory function 
once it is administered to young rats. Because Tg2576 mice 
start to develop plaques after 14 months, the accumulation of 
soluble Aβ*56 in the brains of middle-aged Tg2576 mice may 
be responsible for cognitive deficit, which is independent of 
plaque formation.34 However, it is not clear whether Aβ*56 
is unique to Tg2576 or a universal Aβ oligomer species that 
can be identified across most middle aged transgenic mouse 
lines that develop neuritic plaques at a later time.
From Aβ to synaptic deficits: 
possible mechanisms
A number of mechanisms of action have been proposed for 
the effect of Aβ on synaptic signaling. In cultured cortical 
neurons, Aβ has been found to promote the endocyto-





  reduction of Aβ by γ-secretase inhibitor which suppresses 
the internalization of NMDA receptors. On the other hand, 
lower levels of cell surface NMDA receptors are found 
in APP transgenic mice that carry high levels of Aβ. α-7 
nicotinic receptors (nAChRs), protein phosphatase 2B and 
the striatal-enriched protein (STEP) tyrosine phosphatase 
that are required for endocytosis of NMDA receptors; 
which is correlated to the dephosphorylation of the NMDA 
receptor-2B at Tyr1472.35 Aβ has been shown to inhibit 
NMDA receptor dependent LTP although not the NMDA 
receptor independent LTP or LTD. This inhibition requires 
the activation of microglia and involves inducible nitric 
oxide synthase (iNOS) and superoxide. These inflammatory 
related reactions seem to be necessary for the Aβ mediated 
inhibition of LTP; which could be prevented in the presence 
of minocycline (inhibition of microglia activation), nicotin-
amide adenine dinucleotide phosphate-H oxidase inhibitor, 
or in iNOS knock out mice.36
In differentiated cultures of hippocampal neurons, syn-
thetic ADDLs bind to excitatory pyramidal neurons although 
not γ-aminobutyric acid (GABA)-inergic neurons and are 
associated with postsynaptic density complexes containing 
NMDA receptors. It decreases expression of memory-related 
receptors (NMDA and ephrin-B2) and causes abnormal spine 
morphology and a significant decrease in spine density.37 
The NMDA-evoked cell firing rate has been studied in CA1 
neurons in the rat and Aβ42 significantly increases NMDA 
responses, an effect which is irreversible.38 The peptide 
Aβ25–35 shows a similar effect. On the other hand dendritic 
spine loss in the presence of Aβ oligomers is reversible 
once Aβ is eliminated by antibodies. When exposed to a 
physiological concentration of Aβ oligomers (a picomolar 
concentration), the density of dendritic spines decreases, and 
the active synapses are reduced. Furthermore, the activity 
of NMDA receptors is required for Aβ oligomer to affect 
dendritic spine morphological changes, and NMDA receptor-
mediated calcium influx into dendritic spines decrease in the 
presence of Aβ oligomers.39
Application of Aβ to astrocytes in vitro leads to an 
inhibition of glutamate uptake along with rapid depolarization 
of astroglial membranes. Infusion of Aβ via microdialysis 
in the rat magnocellular nucleus basalis (MBN) leads to an 
acute increase of the extracellular concentration of excitatory 
amino acid neurotransmitters and enhances the intracellular 
accumulation of Ca2+ in the injection area. The effect of Aβ in 
the MBN can be suppressed by the NMDA receptor channel 
blocker dizocilpine maleate MK-801, suggesting multiple 
occurring events upon Aβ insult, eg, astroglial depolarization, 
extracellular glutamate accumulation, intracellular Ca2+ 
increase, and NMDA receptor activation.40 On the other 
hand, an earlier study shows that MK-801 at the dose that 
produces a similar inhibition of NMDA potentials shows no 
effect on LTP, while Aβ produces a significant inhibition of 
NMDA receptor-mediated synaptic potentials.41 Therefore, it 
is possible that Aβ affects multiple pathways leading to the 
inhibition of LTP, and it is important to understand whether 
these downstream pathways are among the main contributors 
to the effect of Aβ on LTP.
Besides NMDA receptors, Aβ also promotes endocytosis 
of synaptic α-amino-3-hydroxyl-5-methyl-4-isoxazole-
propionate receptors (AMPAR), which causes the loss of 
dendritic spines.42 Consistent with this finding, double knock-
in mice expressing mutant APP and presenilin genes show 
age-dependent downscaling of AMPAR-mediated evoked 
currents. Accordingly, age-related deficits in LTP/LTD are 
also found in the double knock-in mice.43
A receptor for advanced glycation end products (RAGE) 
dependent pathway has been proposed for Aβ mediated 
synaptic dysfunction. Inhibition of LTP by Aβ is abolished 
in slices from anti-RAGE antibody-treated wild type mice. 
Furthermore, no inhibition has been observed in slices 
from RAGE knock-out mice or transgenic mice expressing 
a dominant negative mutant of RAGE. Since activation 
of p38 mitogen-activated protein kinase (p38 MAPK) 
phosphorylation is decreased by antibodies against RAGE, 
suppression of LTP inhibition has been achieved by blocking 
p38 MAPK. These studies illustrate a RAGE-dependent 
pathway that involves Aβ induced activation of p38 MAPK 
to impair LTP.44 On the other hand, Aβ has been shown to 
activate the complement cascade and generate complement 
component C5-derived anaphilatoxin C5a, which activates 
MAPK and mediates neuroprotection.45,46 The complex path-
ways downstream of Aβ reflect direct and indirect activation 
of MAPK pathways47 and may have different effect on 
synaptic function.
Recently, cellular prion protein (PrP(C)) has been found to 
bind to Aβ oligomers, and the infectious prion protein PrP(Sc) 
conformation is not required for the interaction.48,49 The 
binding of Aβ oligomers to PrP(C) can be blocked by anti-PrP 
antibodies, and the inhibitory effect on LTP is suppressed.48 
Whether PrP(C) plays a critical role in recognizing Aβ 
oligomers and mediating downstream synaptic response is not 
clear, as conflicting results have been reported on LTP in Aβ 




Aβ oligomers inhibit LTP
Pharmacological inhibition of ion translocation by the 
Na+, K+-adenosine triphosphatease has been observed in 
the presence of micromolar concentrations of Aβ1-42.50 
Inhibition of calcineurin activity by FK506 or cyclosporine 
A reveals the calcineurin-dependent inhibition of LTP by 
Aβ42.51 The disruptions in Ca2+ signaling are caused not only 
by Aβ oligomers but also by amyloid-type oligomers like 
prions and polyglutamine. Amyloid oligomers increase intra-
cellular Ca2+, and Ca2+ signals induced by Aβ42 oligomers 
are derived from extracellular and intracellular Ca2+ sources. 
Treating a fluorescent dye loaded neuroblastoma cell line with 
Aβ oligomers leads to an increase in membrane permeability 
and the leakage of anionic dye. When membrane permeability 
is increased in the presence of Aβ or other oligomers, cells 
with a high transmembrane concentration gradient of Ca2+ 
ion are extremely vulnerable.52
Additional pathways that are implicated in Aβ mediated 
synaptic deficits include altered serine/threonine protein 
kinase (Akt), glycogen synthase kinase3β (GSK3β) together 
with the phosphatase and tensin homolog (PTEN). Exposing 
organotypic slice culture to synthetic Aβ25–35 peptide leads 
to an initial increase then decrease in phosphorylation of Akt 
and GSK3β, followed by an increase of PTEN protein after 
one day of exposure.53
In animals, analysis of APP transgenic mice reveals an 
upregulation of nAChRs along with a decrease of the MAPK 
in hippocampus. The phosphorylation of cyclic adenosine 
monophosphate regulatory element binding (CREB) protein 
is decreased by high levels of Aβ42. Therefore, Aβ42 may 
depend on nAChRs to downregulate MAPK and the phos-
phorylation of CREB protein.54 Accordingly, activation 
of extracellular signal-regulated kinase/MAPK, Ca2+/
calmodulin-dependent kinase II, and the phosphatidylinositol 
3-kinase-activated protein Akt/protein kinase B is disrupted 
in the presence of soluble Aβ. The insulin receptor family 
of tyrosine kinase has been found to mediate Aβ induced 
synaptic deficits and soluble Aβ binds to insulin receptors 
and affects its autophosphorylation in the presence of insulin. 
The Aβ mediated kinase inhibition is similar to that achieved 
by an antagonist of the insulin receptor family of tyrosine 
kinases.55
Rescuing synaptic deficits: amyloid based 
therapeutic intervention
Multiple approaches have been applied to decrease Aβ 
oligomer-induced synaptic dysfunction. Cyclohexanehexol 
stereoisomers have been identified to prevent the formation 
of Aβ oligomers and reduce AD-like pathologies in trans-
genic mouse brains. Impaired cognition and synaptic 
function are reduced in the presence of cyclohexanehexol 
inhibitors.56 Among these stereoisomers, small molecular 
weight scyllo-inositol is found to suppress the inhibitory 
effect of Aβ oligomers on LTP in mouse hippocampus. 
Cerebroventricular injection of Aβ oligomers derived from 
APP overexpressing CHO cells into rat impairs learned 
performance on a complex lever-pressing task. This 
impairment can be rescued in animals drinking scyllo-
inositol containing water.57 Apparently, small molecular 
compounds that block the oligomer formation suppress the 
inhibitory effect of Aβ on LTP.58,59
The rescue of LTP inhibition by Aβ oligomers can also 
be achieved by a monoclonal antibody against Aβ. Earlier 
studies have shown that a monoclonal antibody against 
the mid region of Aβ (m266) reverses memory deficits in 
an object recognition task and a holeboard learning and 
memory task.60 Injection of monoclonal Aβ antibody after 
intracerebroventricular injection of Aβ secreted from APP 
overexpressing cells prevents the inhibition of LTP by Aβ 
oligomers. Interestingly, active immunization shows partial 
effects that correlate positively with levels of Aβ antibodies.61 
In another study, the memory loss in Tg2576 mice can be 
fully reversed upon intraperitoneally dosing with BAM-10, an 
antibody recognizing N-terminus of Aβ. BAM-10 neutralizes 
Aβ assemblies in the brain and prevents them from disrupt-
ing cognitive function.62 Furthermore, soluble Aβ oligomer 
induced spine loss could be rescued by Aβ specific antibod-
ies; this reversible event provides a promising approach for 
therapeutic intervention of AD.39
The most advanced clinical trial with antibody based 
Aβ reduction therapy is at Phase III with bapineuzumab, a 
humanised anti-amyloid-β monoclonal antibody. This was 
based on earlier findings that vaccination with a synthetic Aβ 
reduces plaque load in transgenic mice.63 However, active vac-
cination with AN1792 (β-amyloid [Aß]1-42) failed clinical 
trial, and recent studies with passive vaccine bapineuzumab 
showed some effect on Aβ load. Three ascending dose groups 
at 0.5, 1 and 2 mg/kg of bapineuzumab were administrated up 
to 6 times in mild to moderate AD patients at 13 weeks apart. 
Positron emission tomography (PET) scanning using Carbon-
11-labelled Pittsburgh compound B (11C-PiB) was carried out 
to measure cortical fibrillar amyloid-β load in AD patients. 
Administration of bapineuzumab for 78 weeks led to a reduc-
tion of 11C-PiB retention. Currently there is no imaging based 





and it is not clear why bapineuzumab only improves cognitive 
function in apolipoprotein-E4 non-carriers.
Non-vaccine based therapeutic approaches include 
γ-secretase inhibitors64 and modulators. R-flurbiprofen is 
a non-steroidal anti-inflammatory drug and a γ-secretase 
modulator,  and  treatment  of  transgenic  mice  with 
R-flurbiprofen efficiently reduces Aβ levels.65 However, 
R-flurbiprofen failed Phase III clinical trials for the treatment 
of AD. Semagacestat66–69 is a γ-secretase inhibitor and was 
shown to be effective in reducing plasma Aβ during a recent 
Phase II clinical trial. Begacestat, a γ-secretase modulator, 
reduced both Aβ40 and Aβ42 in transgenic mouse brains and 
reversed cognitive deficits.70
Conclusion
The amyloid hypothesis illustrates a multi-step cascade 
originating from excessive Aβ  generation  to  final 
neuropathological hallmarks found in brains of Alzheimer’s 
patients.71 While potential targets have been explored to block 
the cascade and prevent the onset of the disease, identification 
and validation of Aβ species that are most toxic to neurons 
continues to be a challenge. Aβ oligomers physically or 
functionally interact with multi-components that play intrin-
sic roles in pathways leading to LTP inhibition, and potential 
targets related to these pathways show tremendous promise for 
therapeutic intervention. Current efforts focus on removing 
monomeric and oligomeric Aβ to rescue synaptic dysfunc-
tion, and these approaches are highly promising as they have 
reversed Aβ-induced synaptic deficits. In conclusion, reducing 
oligomeric Aβ formation as well as minimizing its toxicity to 
synapses will provide enhanced protection against neuronal 
loss and eventually delay memory impairment.
Acknowledgments
Some of the studies described in this article were carried 
out in the author’s laboratory and were supported by NIH 
grant AG015379. We would like to thank Dr Shaomin Li for 
helpful discussion.
Disclosure
The author reports no conflicts of interest relevant to this 
research.
References
1.  Selkoe DJ. Translating cell biology into therapeutic advances in Alzheim-
er’s disease. Nature. 1999;399 (suppl):A23–A31.
2.  Xia W. Amyloid inhibitors and Alzheimer’s disease. Curr Opin Investig 
Drugs. 2003;4(1):55–59.
3.  Xia W. Amyloid metabolism and secretases in Alzheimer’s disease. Curr 
Neurol Neurosci Rep. 2001;1:422–427.
  4.  Hyman BT, Tanzi RE, Marzloff K, Barbour R, Schenk D. Kunitz protease 
inhibitor-containing amyloid beta protein precursor immunoreactivity in 
Alzheimer’s disease. J Neuropathol Exp Neurol. 1992; 51(1):76–83.
  5.  Edbauer D, Winkler E, Regula JT, Pesold B, Steiner H, Haass C. 
Reconstitution of gamma-secretase activity. Nat Cell Biol. 2003;5: 
486–488.
  6.  Wolfe MS, Xia W, Ostaszewski BL, Diehl TS, Kimberly WT, Selkoe DJ. 
Two transmembrane aspartates in presenilin-1 required for presenilin 
endoproteolysis and γ-secretase activity. Nature. 1999;398:513–517.
  7.  Yu G, Nishimura M, Arawaka S, et al. Nicastrin modulates presenilin-
mediated notch/glp-1 signal transduction and betaAPP processing. 
Nature. 2000;407(6800):48–54.
  8.  Chen F, Yu G, Arawaka S, et al. Nicastrin binds to membrane-tethered 
Notch. Nat Cell Biol. 2001;3:751–754.
  9.  Goutte C, Tsunozaki M, Hale VA, Priess JR. APH-1 is a multipass mem-
brane protein essential for the Notch signaling pathway in Caenorhab-
ditis elegans embryos. Proc Natl Acad Sci. 2002;99(2):775–779.
  10.  Francis R, McGrath G, Zhang J, et al. aph-1 and pen-2 are required for 
Notch pathway signaling, g-secretase cleavage of bAPP and presenilin 
protein accumulation. Dev Cell. 2002;3:85–97.
  11.  Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synap-
tic plasticity and behavior. Behav Brain Res. 2008;192(1):106–113.
  12.  Xia W, Yang T, Shankar G, et al. A Specific ELISA for Measuring 
Amyloid β-Protein Oligomer in Human Plasma and the Brains of 
Alzheimer Patients. Arch Neurol. 2008;66(2):1–10.
  13.  Lue LF, Kuo YM, Roher AE, et al. Soluble amyloid beta peptide con-
centration as a predictor of synaptic change in Alzheimer’s disease. Am 
J Pathol. 1999;155(3):853–862.
  14.  McLean CA, Cherny RA, Fraser FW, et al. Soluble pool of Abeta amy-
loid as a determinant of severity of neurodegeneration in Alzheimer’s 
disease. Ann Neurol. 1999;46(6):860–866.
  15.  Naslund J, Haroutunian V , Mohs R, et al. Correlation between elevated 
levels of amyloid beta-peptide in the brain and cognitive decline. JAMA. 
2000;283(12):1571–1577.
  16.  Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein 
similar to that in the senile plaques of Alzheimer’s disease is increased 
in vivo by the presenilin 1 and 2 and APP mutations linked to familial 
Alzheimer’s disease. Nature Med. 1996;2(8):864–870.
  17.  Enya M, Morishima-Kawashima M, Yoshimura M, et al. Appearance 
of sodium dodecyl sulfate-stable amyloid beta-protein (Abeta) dimer 
in the cortex during aging. Am J Pathol. 1999;154(1):271–279.
  18.  Podlisny MB, Ostaszewski BL, Squazzo SL, et al. Aggregation of 
secreted amyloid β-protein into SDS-stable oligomers in cell culture. 
J Biol Chem. 1995;270:9564–9570.
  19.  Xia W, Zhang J, Kholodenko D, et al. Enhanced production and 
oligomerization of the 42-residue amyloid beta-protein by Chinese 
hamster ovary cells stably expressing mutant presenilins. J Biol Chem. 
1997;272(12):7977–7982.
  20.  Gravina SA, Ho L, Eckman CB, et al. Amyloid beta protein (A beta) 
in Alzheimer’s disease brain. Biochemical and immunocytochemical 
analysis with antibodies specific for forms ending at A beta 40 or A beta 
42(43). J Biol Chem. 1995;270(13):7013–7016.
  21.  Bitan G, Kirkitadze MD, Lomakin A, Vollers SS, Benedek GB, 
Teplow DB. Amyloid beta -protein (Abeta) assembly: Abeta 40 and 
Abeta 42 oligomerize through distinct pathways. Proc Natl Acad Sci 
U S A. 2003;100(1):330–335.
  22.  Kawarabayashi T, Shoji M, Younkin LH, et al. Dimeric amyloid beta 
protein rapidly accumulates in lipid rafts followed by apolipoprotein 
E and phosphorylated tau accumulation in the Tg2576 mouse model 
of Alzheimer’s disease. J Neurosci. 2004;24(15):3801–3809.
  23.  Mucke L, Masliah E, Yu GQ, et al. High-level neuronal expression of 
A beta 1-42 in wild-type human amyloid protein precursor transgenic 
mice: synaptotoxicity without plaque formation. J Neurosci. 2000; 
20(11):4050–4058.
  24.  Hsia AY, Masliah E, McConlogue L, et al. Plaque-independent 
disruption of neural circuits in Alzheimer’s disease mouse models. Proc 




Aβ oligomers inhibit LTP
  25.  O’Hare E, Weldon DT, Mantyh PW, et al. Delayed behavioral effects 
following intrahippocampal injection of aggregated A beta (1-42). Brain 
Res. 1999;815(1):1–10.
  26.  Kim JH, Anwyl R, Suh YH, Djamgoz MB, Rowan MJ. Use-dependent 
effects of amyloidogenic fragments of (beta)-amyloid precursor protein 
on synaptic plasticity in rat hippocampus in vivo. J Neurosci. 2001; 
21(4):1327–1333.
  27.  Lambert MP, Barlow AK, Chromy BA, et al. Diffusible, nonfribrillar 
ligands derived from Ab-42 are potent central nervous system 
neurotoxins. Proc Natl Acad Sci U S A. 1998;95:6448–6453.
  28.  Gong Y, Chang L, Viola KL, et al. Alzheimer’s disease-affected 
brain: presence of oligomeric A beta ligands (ADDLs) suggests 
a molecular basis for reversible memory loss. Proc Natl Acad Sci 
U S A. 2003;100(18):10417–10422. Epub 12003 Aug 10418.
  29.  Wang HW, Pasternak JF, Kuo H, et al. Soluble oligomers of beta 
amyloid (1-42) inhibit long-term potentiation but not long-term 
depression in rat dentate gyrus. Brain Res. 2002;924(2):133–140.
  30.  Walsh DM, Fadeeva JV, LaVoie MJ, et al. gamma-Secretase 
cleavage and binding to FE65 regulate the nuclear translocation of the 
intracellular C-terminal domain (ICD) of the APP family of proteins. 
Biochemistry. 2003;42(22):6664–6673.
  31.  Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ. Effects 
of secreted oligomers of amyloid beta-protein on hippocampal 
synaptic plasticity: a potent role for trimers. J Physiol. 2006;572(Pt 2): 
477–492.
  32.  Shankar GM, Li S, Mehta TH, et al. Amyloid-beta protein dimers 
isolated directly from Alzheimer’s brains impair synaptic plasticity 
and memory. Nat Med. 2008;14(8):837–842.
  33.  Cleary JP, Walsh DM, Hofmeister JJ, et al. Natural oligomers of 
the amyloid-beta protein specifically disrupt cognitive function. Nat 
Neurosci. 2005;8(1):79–84.
  34.  Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein 
assembly in the brain impairs memory. Nature. 2006;440(7082): 
352–357.
  35.  Snyder EM, Nong Y, Almeida CG, et al. Regulation of NMDA receptor 
trafficking by amyloid-beta. Nat Neurosci. 2005;8(8): 1051–1058.
  36.  Wang Q, Rowan MJ, Anwyl R. Beta-amyloid-mediated inhibition of 
NMDA receptor-dependent long-term potentiation induction involves 
activation of microglia and stimulation of inducible nitric oxide 
synthase and superoxide. J Neurosci. 2004;24(27):6049–6056.
 37.  Lacor PN, Buniel MC, Furlow PW, et al. Abeta oligomer-induced aberrations 
in synapse composition, shape, and density provide a molecular basis for loss 
of connectivity in Alzheimer’s disease. J Neurosci. 2007; 27(4):796–807.
  38.  Molnar Z, Soos K, Lengyel I, Penke B, Szegedi V , Budai D. Enhancement 
of NMDA responses by beta-amyloid peptides in the hippocampus in 
vivo. Neuroreport. 2004;15(10):1649–1652.
  39.  Shankar GM, Bloodgood BL, Townsend M, Walsh DM, Selkoe DJ, 
Sabatini BL. Natural oligomers of the Alzheimer amyloid-beta protein 
induce reversible synapse loss by modulating an NMDA-type 
glutamate receptor-dependent signaling pathway. J Neurosci. 2007; 
27(11):2866–2875.
  40.  Harkany T, Abraham I, Timmerman W, et al. beta-amyloid neurotoxicity 
is mediated by a glutamate-triggered excitotoxic cascade in rat nucleus 
basalis. Eur J Neurosci. 2000;12(8):2735–2745.
  41.  Raymond CR, Ireland DR, Abraham WC. NMDA receptor regulation 
by amyloid-beta does not account for its inhibition of LTP in rat 
hippocampus. Brain Res. 2003;968(2):263–272.
  42.  Hsieh H, Boehm J, Sato C, et al. AMPAR removal underlies Abeta-
induced synaptic depression and dendritic spine loss. Neuron. 2006; 
52(5):831–843.
  43.  Chang EH, Savage MJ, Flood DG, et al. AMPA receptor downscaling 
at the onset of Alzheimer’s disease pathology in double knockin mice. 
Proc Natl Acad Sci U S A. 2006;103(9):3410–3415.
  44.  Origlia N, Righi M, Capsoni S, et al. Receptor for advanced glycation 
end product-dependent activation of p38 mitogen-activated pro-
tein kinase contributes to amyloid-beta-mediated cortical synaptic 
dysfunction. J Neurosci. 2008;28(13):3521–3530.
  45.  Osaka H, Mukherjee P, Aisen P, Pasinetti G. Complement-derived 
anaphylatoxin C5a protects against glutamate-mediated neurotoxicity. 
J Cell Biochem. 1998;73(3):303–311.
  46.  Osaka H, McGinty A, Höepken U, Lu B, Gerard C, Pasinetti G. 
Expression of C5a receptor in mouse brain: role in signal transduction 
and neurodegeneration. Neuroscience. 1999;88:1073–1082.
  47.  Mukherjee P, Pasinetti GM. The role of complement anaphylatoxin 
C5a in neurodegeneration: implications in Alzheimer’s disease.   
J Neuroimmunol. 2000;105(2):124–130.
  48.  Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmat-
ter SM. Cellular prion protein mediates impairment of synaptic 
plasticity by amyloid-beta oligomers. Nature. 2009;457(7233): 
1128–1132.
  49.  Balducci C, Beeg M, Stravalaci M, et al. Synthetic amyloid-beta 
oligomers impair long-term memory independently of cellular prion 
protein. Proc Natl Acad Sci U S A. 2010;107(5):2295–2300.
  50.  Gu QB, Zhao JX, Fei J, Schwarz W. Modulation of Na(+),K(+) pumping 
and neurotransmitter uptake by beta-amyloid. Neuroscience. 2004; 
126(1):61–67.
  51.  Chen QS, Wei WZ, Shimahara T, Xie CW. Alzheimer amyloid beta-
peptide inhibits the late phase of long-term potentiation through 
calcineurin-dependent mechanisms in the hippocampal dentate gyrus. 
Neurobiol Learn Mem. 2002;77(3):354–371.
  52.  Demuro A, Mina E, Kayed R, Milton SC, Parker I, Glabe CG. Calcium 
dysregulation and membrane disruption as a ubiquitous neurotoxic 
mechanism of soluble amyloid oligomers. J Biol Chem. 2005;280(17): 
17294–17300.
  53.  Nassif M, Hoppe J, Santin K, et al. Beta-amyloid peptide toxicity in 
organotypic hippocampal slice culture involves Akt/PKB, GSK-3beta, 
and PTEN. Neurochem Int. 2007;50(1):229–235.
  54.  Dineley KT, Westerman M, Bui D, Bell K, Ashe KH, Sweatt JD. 
Beta-amyloid activates the mitogen-activated protein kinase cascade 
via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro 
and in vivo mechanisms related to Alzheimer’s disease. J Neurosci. 
2001;21(12):4125–4133.
  55.  Townsend M, Mehta T, Selkoe DJ. Soluble Abeta inhibits specific signal 
transduction cascades common to the insulin receptor pathway. J Biol 
Chem. 2007;282(46):33305–33312.
  56.  McLaurin J, Kierstead ME, Brown ME, et al. Cyclohexanehexol 
inhibitors of Abeta aggregation prevent and reverse Alzheimer 
phenotype in a mouse model. Nat Med. 2006;12(7):801–808.
  57.  Townsend M, Cleary JP, Mehta T, et al. Orally available compound 
prevents deficits in memory caused by the Alzheimer amyloid-beta 
oligomers. Ann Neurol. 2006;60(6):668–676.
  58.  Walsh DM, Townsend M, Podlisny MB, et al. Certain inhibitors of 
synthetic amyloid beta-peptide (Abeta) fibrillogenesis block oligomer-
ization of natural Abeta and thereby rescue long-term potentiation.   
J Neurosci. 2005;25(10):2455–2462.
  59.  Walsh DM, Klyubin I, Shankar GM, et al. The role of cell-derived 
oligomers of Abeta in Alzheimer’s disease and avenues for therapeutic 
intervention. Biochem Soc Trans. 2005;33(Pt 5):1087–1090.
  60.  Dodart JC, Bales KR, Gannon KS, et al. Immunization reverses memory 
deficits without reducing brain Abeta burden in Alzheimer’s disease 
model. Nat Neurosci. 2002;5(5):452–457.
  61.  Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta protein 
immunotherapy neutralizes Abeta oligomers that disrupt synaptic 
plasticity in vivo. Nat Med. 2005;11(5):556–561.
  62.  Kotilinek LA, Bacskai B, Westerman M, et al. Reversible memory loss 
in a mouse transgenic model of Alzheimer’s disease. J Neurosci. 2002; 
22(15):6331–6335.
  63.  Schenk  D,  Barbour  R,  Dunn W,  et  al.  Immunization  with 
amyloid-?attenuates Alzheimer-disease-like pathology in the PDAPP 
mouse. Nature. 1999;400:173–177.
  64. Townsend  M,  Qu Y,  Gray A,  et  al.  Oral  treatment  with  a 
gamma-secretase inhibitor improves long-term potentiation in 
a mouse model of Alzheimer’s Disease. J Pharmacol Exp Ther. 
2010;333(1):110–119.Neuropsychiatric Disease and Treatment
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal
Neuropsychiatric Disease and Treatment is an international, peer-
reviewed journal of clinical therapeutics and pharmacology focusing on 
concise rapid reporting of clinical or pre-clinical studies on a range of 
neuropsychiatric and neurological disorders. This journal is indexed on 
PubMed Central, the ‘PsycINFO’ database and CAS, and is the official 
journal of The International Neuropsychiatric Association (INA). The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system, which is all easy to use. Visit 
http://www.dovepress.com/testimonials.php to read real quotes from 
published authors.






  65.  Eriksen JL, Sagi SA, Smith TE, et al. NSAIDs and enantiomers of 
flurbiprofen target gamma-secretase and lower Abeta 42 in vivo. J Clin 
Invest. 2003;112(3):440–449.
  66.  Siemers ER, Quinn JF, Kaye J, et al. Effects of a gamma-secretase 
inhibitor in a randomized study of patients with Alzheimer disease. 
Neurology. 2006;66(4):602–604.
  67.  Siemers ER, Dean RA, Friedrich S, et al. Safety, tolerability, and 
effects on plasma and cerebrospinal fluid amyloid-beta after inhibition 
of gamma-secretase. Clin Neuropharmacol. 2007;30(6):317–325.
  68.  Fleisher AS, Raman R, Siemers ER, et al. Phase 2 safety trial targeting 
amyloid beta production with a gamma-secretase inhibitor in Alzheimer 
disease. Arch Neurol. 2008;65(8):1031–1038.
  69.  Henley DB, May PC, Dean RA, Siemers ER. Development of 
semagacestat (LY450139), a functional gamma-secretase inhibitor, 
for the treatment of Alzheimer’s disease. Expert Opin Pharmacother. 
2009;10(10):1657–1664.
  70.  Mayer SC, Kreft AF, Harrison B, et al. Discovery of begacestat, 
a Notch-1-sparing gamma-secretase inhibitor for the treatment of 
Alzheimer’s disease. J Med Chem. 2008;51(23):7348–7351.
  71.  Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer’s disease: 
progress and problems on the road to therapeutics. Science. 2002; 
297(5580):353–356.